

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 July 2006 (27.07.2006)

PCT

(10) International Publication Number
WO 2006/077441 A1

(51) International Patent Classification:

C07K 16/22 (2006.01) C07K 14/48 (2006.01)

(21) International Application Number:

PCT/GB2006/000238

(22) International Filing Date: 24 January 2006 (24.01.2006)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/645,587 24 January 2005 (24.01.2005) US

(71) Applicants (for all designated States except US): CAM-

BRIDGE ANTIBODY TECHNOLOGY LIMITED [GB/GB]; Milstein Building, Granta Park, Cambridge Cambridgeshire CB1 6GH (GB). ELAN PHARMA INTERNATIONAL LIMITED [IE/IE]; Monksland, Athlone, County Westmeath (IE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): FRANKS, Ruth

[GB/GB]; Cambridge Antibody Technology Limited, Milstein Building, Granta Park, Cambridge Cambridgeshire CB1 6GH (GB). BUCHANAN, Andrew Grier [GB/GB]; Cambridge Antibody Technology Limited, Milstein Building, Granta Park, Cambridge Cambridgeshire CB1 6GH (GB). THOM, Albert George [GB/GB]; Cambridge Antibody Technology Limited, Milstein Building, Granta Park, Cambridge Cambridgeshire CB1 6GH (GB). WELSH, Fraser Ewing [GB/GB]; Cambridge Antibody Technology Limited, Milstein Building, Granta Park, Cambridge Cambridgeshire CB1 6GH (GB). BLAND-WARD, Philip Antony [GB/GB]; Cambridge Antibody Technology Limited, Milstein Building, Granta Park, Cambridge Cambridgeshire CB1 6GH (GB). SLEEMAN, Matthew Alexander [GB/GB]; Cambridge Antibody Technology Limited, Milstein Building, Granta Park, Cambridge Cambridgeshire CB1 6GH (GB). MATTHEWS, Carl Anthony [GB/GB]; Cambridge Antibody Technology

Limited, Milstein Building, Granta Park, Cambridge Cambridgeshire CB1 6GH (GB). HART, Celia Patricia [GB/GB]; Cambridge Antibody Technology Limited, Milstein Building, Granta Park, Cambridge Cambridgeshire CB1 6GH (GB). HAWKINSON, Jon [US/US]; Elan Pharmaceuticals, Inc., 800 Gateway Boulevard, South San Francisco, California CA 94080 (US).

(74) Agents: WALTON, Seán et al.; Mewburn Ellis LLP, York House, 23 Kingsway, London Greater London WC2B 6HP (GB).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SPECIFIC BINDING MEMBERS FOR NGF

(57) Abstract: Specific binding members for Nerve Growth Factor (NGF), in particular anti-NGF antibody molecules, especially human antibody molecules, and especially those that neutralise NGF activity. Methods for using anti-NGF antibody molecules in diagnosis or treatment of NGF related disorders, including pain, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, other diseases of airway inflammation, diabetic neuropathy, cardiac arrhythmias, HIV, arthritis, psoriasis and cancer.

WO 2006/077441 A1